查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1934930

鴉片類藥物治療市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、診斷程序、症狀、最終用戶、地區和競爭格局分類，2021-2031 年）

Opisthorchiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Diagnostic Procedure, By Symptom, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球斜視治療市場預計將從 2025 年的 4.2317 億美元成長到 2031 年的 6.5747 億美元，複合年成長率為 7.62%。

該板塊主要關注驅蟲藥的分銷，特別是用於治療由肝吸蟲（Opisthorchis viverrini）和貓肝吸蟲（Opisthorchis felinus）引起的肝吸蟲感染疾病的吡喹酮。市場成長主要受東南亞和東歐流行地區持續的疾病負擔所驅動，這些地區的國家公共衛生計畫需要不斷採購治療方法。此外，政府加大對大規模藥物管理活動的投入以及加強監測也是推動產業發展的關鍵因素。世界衛生組織（WHO）肝吸蟲病研究與控制合作中心發布的2024年數據顯示，大湄公河全部區域肝吸蟲感染的總體盛行率為21.11%，證實了這些高風險地區對有效治療方法的巨大需求。

市場概覽
預測期 2027-2031
市場規模：2025年 4.2317億美元
市場規模：2031年 6.5747億美元
複合年成長率：2026-2031年 7.62%
成長最快的細分市場 造影
最大的市場 亞太地區

儘管有這些正面因素，市場擴張仍面臨諸多障礙：在疾病高發生率的偏遠農村地區，靈敏的診斷工具取得管道有限。依賴靈敏度通常較低的顯微鏡糞便檢驗會導致診斷延誤，從而限制了可治療的患者群體。此外，除吡喹酮外缺乏其他替代治療方法，增加了抗藥性的風險，進一步加劇了市場長期永續性。

市場促進因素

在流行地區，肝吸蟲感染率的不斷上升是市場成長的主要促進因素，尤其是在東南亞，這種寄生蟲在農村人口中根深蒂固。不斷上升的感染率導致對驅蟲藥物的持續需求，因為公共衛生機構正努力控制感染循環，而傳統飲食習慣（包括食用生魚）又加劇了感染循環。這種持續的流行狀況需要持續依賴藥物干預來降低發病率並避免嚴重的肝臟併發症。根據《貧窮傳染病》雜誌2024年5月通報，寮國人民民主共和國肝吸蟲感染的總盛行率為34.06%，顯著高於區域平均水平，凸顯了在這些高負擔地區採取治療措施的迫切性。

同時，各國政府為因應寄生蟲病所採取的策略性舉措，正透過加強檢測和根除工作，改變市場格局。世界各地的衛生部門都將根除肝吸蟲作為優先事項，以預防膽管癌等繼發性併發症，並擴大吡喹酮的採購和供應。例如，根據《老虎》雜誌2024年2月報道，泰國衛生署製定了一項雄心勃勃的目標，即透過對高風險族群進行全面篩檢，到2025年將肝吸蟲感染率降低到1%以下。這項政策的根本動力在於疾病帶來的嚴重長期健康風險。根據美國國立衛生研究院2024年12月發表的研究，泰國東北部膽管癌的年齡調整發生率仍然極高，為每10萬人年13.4例，這亟需採取積極的預防和治療策略。

市場挑戰

全球華支睾吸蟲病治療市場的成長受到偏遠農村地區缺乏準確診斷工具的顯著阻礙。在高流行地區，依賴靈敏度低的顯微鏡糞便檢驗常常漏診輕症感染。這種診斷缺口導致假陰性率居高不下，造成大量感染者未確診。因此，驅蟲藥的潛在市場被人為地限制，因為藥品採購訂單通常是基於確診病例數，而非實際的流行病學負擔。

無法準確識別患者直接阻礙了治療機構的收入成長。當國家衛生計畫由於監測數據不足而無法掌握感染的真實規模時，就無法證明增加吡喹酮採購預算的合理性。這種對疾病嚴重程度的系統性低估造成了疾病持續流行與市場表現之間的脫節。根據「聯合抗擊被忽視的熱帶疾病組織」（Uniting to Combat NTDs）預測，到2024年，全球約有16.2億人需要接受被忽視的熱帶疾病（NTD）治療，但由於病例發現不足等障礙，治療覆蓋率仍有顯著缺口。這種差距凸顯了診斷方面的局限性如何嚴重限制了該行業的商業性潛力。

市場趨勢

將治療納入膽管癌預防計劃的舉措，從根本上重塑了抗寄生蟲療法的策略部署，將寄生蟲控制與癌症控制直接聯繫起來。公共衛生通訊協定正日益將吡喹酮納入更廣泛的監測體系，例如膽管癌篩檢和護理計劃，以預防與長期感染相關的致癌進展。這一轉變使市場地位從單純的驅蟲藥提升為重要的腫瘤預防策略，並確保政府對治療的持續投入。 2024年2月發表在《亞太癌症預防日誌》上的一項針對泰國東北部膽管癌的分析報告顯示，在為期10年的篩檢期內，該地區膽管癌的總體發生率為每10萬人32例，這印證了此類綜合干預模式的必要性。

同時，「同一健康」疾病控制模式的應用正將市場從人類治療擴展到環境和宿主管理領域。這項綜合策略利用先進的空間建模技術來識別涉及中間宿主的感染熱點，並指導更精準的社區介入資源分配。透過針對寄生蟲的生態週期，這些模型正在推動高風險地區對監測工具和標靶治療宣傳活動的需求。根據2024年11月發表於《獸醫學前沿》（Frontiers in Veterinary Science）的一項關於水資源中肝吸蟲感染空間預測的研究，最佳化的地理加權回歸模型實現了R² 0.800的預測準確率，顯示在識別和控制複雜水環境中的感染源方面取得了顯著進步。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球肝吸蟲病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（藥物治療、手術）
    • 透過診斷程序（造影、MRI、超音波、 電腦斷層掃描、其他）
    • 根據症狀（黃疸、腹瀉、發燒、脾腫大、體重減輕、心搏過速等）
    • 按最終使用者（醫院/診所、門診護理中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美肝吸蟲病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲肝吸蟲病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區鴉片類藥物治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲肝吸蟲病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲肝吸蟲病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球肝吸蟲病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Cipla Inc.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck KGaA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Mankind Pharma Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 8163

The Global Opisthorchiasis Treatment Market is projected to expand from USD 423.17 Million in 2025 to USD 657.47 Million by 2031, reflecting a CAGR of 7.62%. This sector primarily focuses on the distribution of anthelmintic agents, particularly praziquantel, which are used to eliminate parasitic liver fluke infections caused by Opisthorchis viverrini and Opisthorchis felineus. The market's growth is largely sustained by the ongoing disease burden in endemic areas of Southeast Asia and Eastern Europe, which necessitates consistent procurement of therapeutic regimens by national public health programs. Furthermore, increased government investment in mass drug administration efforts and enhanced surveillance systems act as key catalysts for industry development. Data from the WHO Collaborating Centre for Research and Control of Opisthorchiasis in 2024 indicates a pooled prevalence of Opisthorchis viverrini infection of 21.11% across the Greater Mekong Subregion, underscoring the substantial demand for effective treatments in these high-risk territories.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 423.17 Million
Market Size 2031USD 657.47 Million
CAGR 2026-20317.62%
Fastest Growing SegmentCholangiography
Largest MarketAsia Pacific

Despite these positive drivers, market expansion faces a significant obstacle in the form of limited access to precise diagnostic tools in remote rural communities where the disease is most common. The dependence on microscopic stool examinations, which frequently exhibit low sensitivity, results in underdiagnosis and consequently limits the patient population identified for treatment. Additionally, the lack of alternative therapeutic options beyond praziquantel creates a vulnerability regarding potential drug resistance, further complicating the long-term sustainability of the market.

Market Driver

The increasing prevalence of opisthorchiasis in endemic regions serves as a major engine for market growth, especially within Southeast Asia where the parasite is deeply rooted in rural populations. Elevated infection rates fuel a continuous demand for anthelmintic medications as public health agencies attempt to manage transmission cycles promoted by traditional dietary practices involving raw fish consumption. This persistent endemicity guarantees a steady dependence on pharmacological interventions to reduce morbidity and avert severe hepatic complications. As reported by Infectious Diseases of Poverty in May 2024, the pooled prevalence of Opisthorchis viverrini infection in the Lao People's Democratic Republic was 34.06 percent, a figure notably above the regional average, highlighting the urgent need for therapeutic measures in these high-burden zones.

Concurrently, strategic government initiatives aimed at controlling parasitic diseases are transforming the market through intensified screening and eradication efforts. National health authorities are prioritizing the elimination of liver flukes to prevent downstream complications such as bile duct cancer, leading to increased procurement and distribution of praziquantel. For example, The Thaiger reported in February 2024 that the Thai Ministry of Public Health set a strict goal to reduce the liver fluke infection rate to below 1 percent of the population by 2025 via comprehensive screening of at-risk demographics. These policy mandates are bolstered by the serious long-term health risks linked to the condition; a study published by the National Institutes of Health in December 2024 noted that Northeastern Thailand maintains a critically high Age-Standardized Rate of cholangiocarcinoma at 13.4 per 100,000 person-years, requiring aggressive preventive treatment strategies.

Market Challenge

Growth in the Global Opisthorchiasis Treatment Market is significantly hampered by the scarcity of accurate diagnostic tools within remote rural communities. In these high-prevalence zones, the reliance on microscopic stool examination, known for its low sensitivity, often fails to identify lighter infections. This diagnostic shortfall leads to a high frequency of false negatives, leaving a large portion of the infected population undiagnosed. As a result, the addressable market for anthelmintic agents is artificially constrained, given that pharmaceutical procurement orders are typically based on confirmed case numbers rather than the actual epidemiological load.

The inability to accurately identify patients directly obstructs revenue growth for treatment providers. When national health programs are unable to verify the true scope of infection due to inadequate surveillance data, they cannot justify increased budgetary allocations for purchasing praziquantel. This systemic underestimation of disease volume generates a discrepancy between the persistent prevalence of the disease and market performance. According to Uniting to Combat NTDs, reports in 2024 indicated that while approximately 1.62 billion people globally needed interventions for neglected tropical diseases, a significant gap in treatment coverage remains due to barriers such as insufficient case detection. This disparity highlights how diagnostic limitations severely restrict the sector's realized commercial potential.

Market Trends

The integration of treatment into cholangiocarcinoma prevention programs is fundamentally reshaping the strategic deployment of anthelmintic therapies by connecting parasite eradication directly to cancer control measures. Public health protocols are increasingly incorporating praziquantel administration into broader screening structures, such as the Cholangiocarcinoma Screening and Care Program, to halt the carcinogenic progression associated with long-term infection. This transition elevates the market from simple deworming efforts to essential oncology prevention strategies, ensuring sustained government funding for therapeutic procurement. As highlighted in the Asian Pacific Journal of Cancer Prevention in February 2024, an article analyzing cholangiocarcinoma in Northeastern Thailand reported an overall incidence rate of 32 per 100,000 population over a decade-long screening period, reinforcing the necessity of these integrated intervention models.

Simultaneously, the adoption of One Health disease control models is broadening the market's scope beyond human therapeutics to include environmental and reservoir host management. This holistic strategy employs advanced spatial modeling to pinpoint transmission hotspots involving intermediate hosts, thereby directing more precise resource allocation for community-based interventions. By targeting the parasite's ecological cycle, these models stimulate demand for surveillance tools and focused treatment campaigns in high-risk areas. According to Frontiers in Veterinary Science in November 2024, a study on the spatial prediction of liver fluke infection in water resources demonstrated that an optimized geographically-weighted regression model achieved a prediction accuracy R-squared value of 0.800, significantly improving the capability to identify and manage infection sources in complex aquatic environments.

Key Market Players

  • Cipla Inc.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck KGaA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Mankind Pharma Limited

Report Scope

In this report, the Global Opisthorchiasis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opisthorchiasis Treatment Market, By Type

  • Medications
  • Surgery

Opisthorchiasis Treatment Market, By Diagnostic Procedure

  • Cholangiography
  • MRI
  • Ultrasonography
  • CT scan
  • Others

Opisthorchiasis Treatment Market, By Symptom

  • Jaundice
  • Diarrhea
  • Fever
  • Splenomegaly
  • Weight loss
  • Tachycardia
  • Others

Opisthorchiasis Treatment Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Opisthorchiasis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opisthorchiasis Treatment Market.

Available Customizations:

Global Opisthorchiasis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opisthorchiasis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Medications, Surgery)
    • 5.2.2. By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)
    • 5.2.3. By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Opisthorchiasis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Diagnostic Procedure
    • 6.2.3. By Symptom
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Opisthorchiasis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Diagnostic Procedure
        • 6.3.1.2.3. By Symptom
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Opisthorchiasis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Diagnostic Procedure
        • 6.3.2.2.3. By Symptom
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Opisthorchiasis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Diagnostic Procedure
        • 6.3.3.2.3. By Symptom
        • 6.3.3.2.4. By End User

7. Europe Opisthorchiasis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Diagnostic Procedure
    • 7.2.3. By Symptom
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Opisthorchiasis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Diagnostic Procedure
        • 7.3.1.2.3. By Symptom
        • 7.3.1.2.4. By End User
    • 7.3.2. France Opisthorchiasis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Diagnostic Procedure
        • 7.3.2.2.3. By Symptom
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Opisthorchiasis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Diagnostic Procedure
        • 7.3.3.2.3. By Symptom
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Opisthorchiasis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Diagnostic Procedure
        • 7.3.4.2.3. By Symptom
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Opisthorchiasis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Diagnostic Procedure
        • 7.3.5.2.3. By Symptom
        • 7.3.5.2.4. By End User

8. Asia Pacific Opisthorchiasis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Diagnostic Procedure
    • 8.2.3. By Symptom
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Opisthorchiasis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Diagnostic Procedure
        • 8.3.1.2.3. By Symptom
        • 8.3.1.2.4. By End User
    • 8.3.2. India Opisthorchiasis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Diagnostic Procedure
        • 8.3.2.2.3. By Symptom
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Opisthorchiasis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Diagnostic Procedure
        • 8.3.3.2.3. By Symptom
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Opisthorchiasis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Diagnostic Procedure
        • 8.3.4.2.3. By Symptom
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Opisthorchiasis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Diagnostic Procedure
        • 8.3.5.2.3. By Symptom
        • 8.3.5.2.4. By End User

9. Middle East & Africa Opisthorchiasis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Diagnostic Procedure
    • 9.2.3. By Symptom
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Opisthorchiasis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Diagnostic Procedure
        • 9.3.1.2.3. By Symptom
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Opisthorchiasis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Diagnostic Procedure
        • 9.3.2.2.3. By Symptom
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Opisthorchiasis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Diagnostic Procedure
        • 9.3.3.2.3. By Symptom
        • 9.3.3.2.4. By End User

10. South America Opisthorchiasis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Diagnostic Procedure
    • 10.2.3. By Symptom
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Opisthorchiasis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Diagnostic Procedure
        • 10.3.1.2.3. By Symptom
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Opisthorchiasis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Diagnostic Procedure
        • 10.3.2.2.3. By Symptom
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Opisthorchiasis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Diagnostic Procedure
        • 10.3.3.2.3. By Symptom
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Opisthorchiasis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cipla Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson
  • 15.3. Sun Pharmaceutical Industries Ltd.
  • 15.4. Merck KGaA
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Pfizer Inc.
  • 15.7. GlaxoSmithKline plc
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. AbbVie Inc
  • 15.10. Mankind Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer